These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 8549019

  • 1. Clinical experience with acarbose: results of a Canadian multicentre study.
    Rodger NW, Chiasson JL, Josse RG, Hunt JA, Palmason C, Ross SA, Ryan EA, Tan MH, Wolever TM.
    Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
    Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, McGill JB.
    Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
    Costa B, Piñol C.
    Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. One-year acarbose treatment raises fasting serum acetate in diabetic patients.
    Wolever TM, Radmard R, Chiasson JL, Hunt JA, Josse RG, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH.
    Diabet Med; 1995 Feb; 12(2):164-72. PubMed ID: 7743764
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
    Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, Schimel D, Weiss S, Taylor T, Krol A, Magner J.
    Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
    Hoffmann J, Spengler M.
    Am J Med; 1997 Dec; 103(6):483-90. PubMed ID: 9428831
    [Abstract] [Full Text] [Related]

  • 15. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
    Bayraktar M, Van Thiel DH, Adalar N.
    Diabetes Care; 1996 Mar; 19(3):252-4. PubMed ID: 8742572
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
    Coniff RF, Shapiro JA, Seaton TB.
    Arch Intern Med; 1994 Nov 14; 154(21):2442-8. PubMed ID: 7979840
    [Abstract] [Full Text] [Related]

  • 20. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
    Coniff RF, Shapiro JA, Seaton TB, Bray GA.
    Am J Med; 1995 May 14; 98(5):443-51. PubMed ID: 7733122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.